Co-Amlessa 2 mg/5 mg/0,625 mg tablety Սլովակիա - սլովակերեն - ŠÚKL (Štátny ústav pre kontrolu liečiv)

co-amlessa 2 mg/5 mg/0,625 mg tablety

krka, d.d., novo mesto, slovinsko - perindopril,amlodipín a indapamid - 58 - hypotensiva

Kigabeq Եվրոպական Միություն - սլովակերեն - EMA (European Medicines Agency)

kigabeq

orphelia pharma sas - vigabatrin - spasms, infantile; epilepsies, partial - antiepileptiká, - kigabeq je uvedené v dojčatá a deti od 1 mesiaca na menej ako 7 rokov na:liečbu v monotherapy infantilné kŕče (west syndróm). liečba v kombinácii s inými antiepileptic liekov pre pacientov s odolné čiastočné epilepsia (ohniskový výskyt záchvatov) s alebo bez sekundárnej zovšeobecnenie, že je tam, kde iné vhodné lieku kombinácie sa ukázali ako nedostatočné alebo neboli tolerované.

Phelinun Եվրոպական Միություն - սլովակերեն - EMA (European Medicines Agency)

phelinun

adienne s.r.l. s.u. - melphalan hydrochloride - multiple myeloma; hodgkin disease; lymphoma, non-hodgkin; precursor cell lymphoblastic leukemia-lymphoma; leukemia, myeloid, acute; neuroblastoma; ovarian neoplasms; hematopoietic stem cell transplantation - antineoplastické činidlá - high-dose of phelinun used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of:multiple myeloma,malignant lymphoma (hodgkin, non-hodgkin lymphoma),acute lymphoblastic and myeloblastic leukemia,childhood neuroblastoma,ovarian cancer,mammary adenocarcinoma. phelinun in combination with other cytotoxic medicinal products is indicated as reduced intensity conditioning (ric) treatment prior to allogeneic haematopoietic stem cell transplantation (allo-hsct) in malignant haematological diseases in adults. phelinun in combination with other cytotoxic medicinal products is indicated as conditioning regimen prior to allogeneic haematopoietic stem cell transplantation in haematological diseases in the paediatric population as:myeloablative conditioning (mac) treatment in case of malignant haematological diseasesric treatment in case of non-malignant haematological diseases.